B. Slama

发表

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

P. Cony-Makhoul, V. Ugo, E. Lippert, 2021, Blood advances.

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes

B. Drénou, P. Fenaux, S. Ducamp, 2018, Haematologica.

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.

A. Stamatoullas, P. Fenaux, N. Vey, 2011, Leukemia research.

Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopenia.

J. Viallard, H. Maisonneuve, B. Godeau, 2017, American journal of blood research.

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.

J. Rossi, F. Roudot-thoraval, P. Bierling, 2011, Blood.

A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO.

A. Stamatoullas, S. Chevret, P. Fenaux, 2013 .

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO

R. Schlenk, K. Metzeler, K. Götze, 2022, Leukemia.

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

M. Delforge, J. Franklin, U. Platzbecker, 2017, Leukemia.

Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry

P. Fenaux, E. Hellström-Lindberg, U. Germing, 2013 .

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

S. Chevret, E. Wattel, P. Fenaux, 2010 .

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

A. Stamatoullas, P. Fenaux, L. Adès, 2005 .

Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux

G. Salles, J. Viallard, L. Galicier, 2019, American journal of hematology.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2016, Blood.

Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial

C. Gaud, J. Viallard, P. Agapé, 2016, BMC Immunology.

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms

F. Bertucci, D. Birnbaum, P. Finetti, 2012, Genes, chromosomes & cancer.

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe

G. Salles, P. Zinzani, A. Bosi, 2022, eJHaem.

High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study.

A. Stamatoullas, M. Béné, P. Fenaux, 2009 .

Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.

J. Rossi, J. Cauvin, K. Ghomari, 2006, Haematologica.

Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study

P. Cony-Makhoul, O. Decaux, C. Dumontet, 2023, American journal of hematology.

Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

B. Pégourié, I. Yakoub-Agha, M. Mohty, 2012, European journal of haematology.

Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.

G. Salles, F. Roudot-thoraval, P. Bierling, 2014, Blood.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

A. Stamatoullas, P. Cony-Makhoul, S. Chevret, 2016, Leukemia.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry

A. Savic, P. Fenaux, E. Hellström-Lindberg, 2019, Haematologica.

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia

J. Viallard, F. Rodeghiero, A. Salama, 2018, Journal of hematology.

Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.

D. Birnbaum, L. Xerri, B. Delaval, 2005, International journal of oncology.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

B. Nilsson, R. Klein, B. Pégourié, 2019, Leukemia.

Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT).

B. Pégourié, O. Decaux, X. Leleu, 2017 .

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL

V. Leblond, C. Dartigeas, C. Tapprich, 2022, Clinical Hematology International.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study

S. Leprêtre, A. Delmer, S. Choquet, 2019, Leukemia & lymphoma.

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs

O. Decaux, A. Lamblin, P. Moreau, 2013, Thrombosis and Haemostasis.

Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

P. Fenaux, E. Hellström-Lindberg, U. Germing, 2015, British journal of haematology.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.

P. Sonneveld, P. Moreau, L. Frenzel, 2020, The Lancet. Haematology.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

M. Vekemans, P. Moreau, H. Avet-Loiseau, 2022, Blood.

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

A. Stamatoullas, M. Béné, P. Fenaux, 2013, Annals of Hematology.

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

K. Tarte, R. Houot, L. Xerri, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction

D. Sène, M. Hamidou, C. Denier, 2021, Stroke.

Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French “ATU” program) by the French Intergroup of Myeloproliferative Neoplasms (FIM).

P. Cony-Makhoul, B. Drénou, Anne Quinquenel, 2012 .

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.

R. Bouabdallah, D. Coso, N. Vey, 2023, Hematology.

PS1377 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY

P. Sonneveld, P. Moreau, L. Frenzel, 2019, HemaSphere.

Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2015 .

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

D. Birnbaum, E. Solary, B. Quesnel, 2010, Leukemia.

Safety and Efficacy Of Rituximab In adult’s Immune Thrombocytopenia (ITP) : Results After One-Year Of Follow-Up In 252 Patients From The Prospective French ITP-Ritux Registry

P. Bierling, A. Delmer, J. Viallard, 2013 .

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma

R. Bouabdallah, D. Coso, N. Vey, 2023, Hematology.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2016, Blood.

Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs)

E. Wattel, P. Fenaux, N. Vey, 2010 .

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

M. Macro, C. Touzeau, K. Laribi, 2024, Nature medicine.